Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47,898,935
-
Total 13F shares
-
51,775,808
-
Share change
-
-439,104
-
Total reported value
-
$3,833,648,345
-
Put/Call ratio
-
137%
-
Price per share
-
$74.03
-
Number of holders
-
260
-
Value change
-
-$28,085,090
-
Number of buys
-
128
-
Number of sells
-
120
Institutional Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2022
As of 30 Sep 2022,
HAEMONETICS CORP - Common Stock (HAE) was held by
260 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
51,775,808 shares.
The largest 10 holders included
Capital Research Global Investors, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, Neuberger Berman Group LLC, STATE STREET CORP, FRANKLIN RESOURCES INC, Fisher Asset Management, LLC, SCHRODER INVESTMENT MANAGEMENT GROUP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
260
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.